Vizgen
Laboratory Equipment · Bioinformatics
$341.6Mtotal raised · 9 rounds on record
$47.8Mlatest round · Series E · Dec 2025 · 10 mo ago
1backers · ARCH Venture Partners
26team · US Form 5500 (plan participants) · Dec 2025 · -73% in a year
Overview
Explore the future of spatial biology with Vizgen’s multiomics platforms. Uncover cellular insights through spatial transcriptomics and proteomics.
Funding and backers
Total raised
$341.6M
9 rounds on record
Latest round
$47.8M
Series E · Dec 2025 · 10 mo ago
Team
26
US Form 5500 (plan participants) · Dec 2025 · -73% in a year
Backers
1
ARCH Venture Partners
The money's age
Fresh money
10 months since the last round · not hiring
Momentum
20/100
fresh money
Last sign of life
1 mo ago
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Apr 15
Launched Vizgen Launches New Panels and AI Segmentation Tools to Advance Spatial Biology Research · vizgen.com
Dec 29, 2025
Raised a round Series E $47.8M · SEC Form D
Oct 1, 2025
Took on debt financing $3.5M · SEC Form D
2025
Team of 96 was 28 · US Form 5500 (plan participants)
Oct 8, 2024
Raised a round Venture round $107.6M · SEC Form D
Jul 11, 2024
Raised a round Venture round $3.3M · SEC Form D
Apr 3, 2023
Launched Vizgen Launches the MERSCOPE PanNeuro Cell Type Predesigned Panel · benzinga.com
Apr 21, 2022
Raised a round Series C $85.2M · SEC Form D
Mar 26, 2021
Raised a round Series B $37M · SEC Form D
Oct 1, 2019
Raised a round Venture round $14M · SEC Form D
Jun 13, 2019
Raised a round Venture round $26.5M · SEC Form D
2019
Founded
Jul 6, 2017
Raised a round Venture round $20.2M · SEC Form D
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Series E | Dec 2025 | $47.8M | — | SEC Form D |
| Debt Financing | Oct 2025 | $3.5M | — | SEC Form D |
| Venture round | Oct 2024 | $107.6M | — | SEC Form D |
| Venture round | Jul 2024 | $3.3M | — | SEC Form D |
| Series C | Apr 2022 | $85.2M | — | SEC Form D |
| Series B | Mar 2021 | $37M | — | SEC Form D |
| Venture round | Oct 2019 | $14M | — | SEC Form D |
| Venture round | Jun 2019 | $26.5M | — | SEC Form D |
| Venture round | Jul 2017 | $20.2M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Ultivue, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Michael NatanExecutive Officer, DirectorSEC Form D
Dr. Peidong WangExecutive Officer, DirectorSEC Form D
Dr. Philip GardellaExecutive OfficerSEC Form D
Dr. Jiang HeExecutive OfficerSEC Form D
Philip GardellaExecutive OfficerSEC Form D
Terry LoDirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
backs Strand AI, Origin Bio
backs Cellanome
Similar startupsby what they do, their industry and backers
Dive deeper. Explore biology at its true scale. CubaseBio is a Stockholm-based spatial biology company, founded by innovators in science…
Next Generation Spatial Biology: AmberGen’s patented Miralys™ Photocleavable Mass-Tag Imaging Significantly Boosts the Capability of Mass…
The Cellanome live-cell, multimodal platform links molecular, functional, and temporal data from the same cells over time. Our proprietary…
ImmPro offers intact proteoform analysis by using top-down proteomics workflows via single-ion mass spectrometry.
Unlock population-scale spatial multiomics with G4X™. 500-plex RNA, 18-plex protein, and fH&E at subcellular resolution.
Spatial proteomics from H&E. Lattice predicts spatially resolved protein-marker maps from routine H&E, delivered as virtual mIF channels.
Visa sponsorship
3 ▼ 57%
H-1B filings in 12 months
$141k
Median offered salary
0
Open roles in United States
Who they sponsor
Other biological scientists
2
Biochemists and biophysicists
1
In the register as Vizgen, Inc., Cambridge, MA (+1 more)
Other sponsors in the same field
Sandbox 
Seer 
Versatope Therapeutics 
Panome Bio
Alert me
US Department of Labor · latest filing Mar 30, 2026 · Visa details by country
Financials
Total raised
$345.1M
Latest round
Series E
Funding rounds
9
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series E | 2025 | $47.8M | Details |
| Debt Financing | 2025 | $3.5M | Details |
| Venture - Series Unknown | 2024 | $107.6M | Details |
| Venture - Series Unknown | 2024 | $3.3M | Details |
| Series C | 2022 | $85.2M | Details |
| Series B | 2021 | $37M | Details |
| Venture - Series Unknown | 2019 | $14M | Details |
| Venture - Series Unknown | 2019 | $26.5M | Details |
| Venture - Series Unknown | 2017 | $20.2M | Details |
People
Michael Natan
Executive Officer, Director
Dr. Peidong Wang
Executive Officer, Director
Dr. Philip Gardella
Executive Officer
Dr. Jiang He
Executive Officer
Philip Gardella
Executive Officer
Terry Lo
Director
Robert Carson
Executive Officer, Director
Seth Benson
Executive Officer
Simona Levi
Executive Officer
Chris Guiffre
Executive Officer
Andrew Stevenson
Director
Peng Yin
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
ARCH Venture PartnersVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
Vizgen to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting
Company plans to showcase new volumetric MERFISH datasets in mouse brain and human neurodegenerative brain tissue, generated on the existing MERSCOPE Ultra Platform WALTHAM, Mass. - June 8, 2026 - Vizgen, Inc., a leader in spatial multiomics and developer
Read more
Report
Vizgen to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting
Vizgen to Advance Cell Atlases with New Volumetric Tissue Mapping Spatial Data and Services at HCA 2026 Meeting
Read more
Report
A spatial atlas of the healthy human liver redefines mammalian liver zonation
Yakubovsky et al., Nature, 2026 A new spatial transcriptomics atlas of the healthy human liver, published in Nature by Yakubovsky and colleagues at the Weizmann Institute of Science with collaborators at Sheba Medical Center and Mayo Clinic, demonstrates
Read more
Report
Vizgen Launches New Panels and AI Segmentation Tools to Advance Spatial Biology Research
Pre-designed and Add-on gene panels are a new means of accessing Vizgen's validation and customization capabilities Extended range of cell segmentation models reflective of ongoing initiative to streamline advanced downstream analysis Waltham, Mass. - Apr
Read more
Report
Vizgen Founder Professor Xiaowei Zhuang Awarded 2026 Ernest Solvay Prize
Prize celebrates breakthrough work that resulted in the MERSCOPE Platform Waltham, Mass. - March 31, 2026 - Xiaowei Zhuang, PhD, the David B. Arnold, Jr. Professor of Science at Harvard University and Howard Hughes Medical Institute Investigator, was rece
Read more
Report
AGBT: Spatial Biology Field 'Maturing' as Updates Well-Received, if Not Flashy
Mar 04, 2026 Andrew P. Han Huanjia Zhang NEW YORK - New developments in spatial biology technology had a muted reception at this year's Advances in Genome Biology and Technology general meeting, as sequencing technology developments stole the headlines. S
Read more
Report
Vizgen to Debut Spatial Multiomics Roadmap at AGBT 2026
Vizgen will expand applications of MERSCOPE Ultra platform to include spatially-resolved molecular profiling of organoids; company has expansive pipeline and is progressing toward multiple breakthrough capabilities Waltham, Mass. - February 19, 2026 - Viz
Read more
Report
Vizgen: $48 Million Funding Raised To Scale Spatial Multi-Omics Platform
Vizgen, a spatial multi-omics company, announced it has closed a $48 million financing led by ARCH Venture Partners and co-led by M Ventures and Northpond Ventures, with participation from existing investors.
Read more
Report
Vizgen Raises $48M in Financing to Fuel Commercial Growth, Path to Profitability
Jan 08, 2026 Huanjia Zhang NEW YORK - Vizgen said on Thursday that it has closed a $48 million financing round to further support its commercial growth. The round was led by Arch Venture Partners, M Ventures, and Northpond Ventures, with participation fro
Read more
Report
Looking Ahead to 2026: A Vizgen View from Our CEO
Dear Vizgen Family, At Vizgen, 2025 was one of both significant evolution and steadfastness. We bolstered our protein and co-detection capabilities, successfully resolved our prior litigation and introduced new, class-leading chemistry. At the same time,
Read more
Report
Show more news
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Cambridge
United States
HQ
Waltham
United States
Regional office
About Vizgen